Solifenacin for the treatment of overactive bladder

By Robinson Dudley   Cardozo Linda  

Therapy, Vol. 8, Iss. 6, 2011-11 ,pp. : 691-701

Future Medicine

Access to resources Recommend Favorite

Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER

By Zinner Norman   Noe Les   Rasouliyan Lawrence   Marshall Thomas   Seifeldin Raafat  

Current Medical Research and Opinion, Vol. 24, Iss. 6, 2008-06 ,pp. : 1583-1591

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom

By Hart Warren Mark   Abrams Paul   Munro Vicki   Retsa Peny   Nazir Jameel  

Journal of Medical Economics, Vol. 16, Iss. 10, 2013-10 ,pp. : 1246-1254

Informa Healthcare

Access to resources Recommend Favorite

Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mg

By Brunton Stephen   Kuritzky Louis  

Current Medical Research and Opinion, Vol. 21, Iss. 1, 2005-01 ,pp. : 71-80

Informa Healthcare

Access to resources Recommend Favorite

The cost-effectiveness of solifenacin vs. trospium in the treatment of patients with overactive bladder in the German National Health Service

By Nazir J.   Hart W.M.  

Journal of Medical Economics, Vol. 17, Iss. 6, 2014-06 ,pp. : 408-414

Informa Healthcare

Access to resources Recommend Favorite